102 related articles for article (PubMed ID: 29972300)
21. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
22. Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Cai SF; Chu SH; Goldberg AD; Parvin S; Koche RP; Glass JL; Stein EM; Tallman MS; Sen F; Famulare CA; Cusan M; Huang CH; Chen CW; Zou L; Cordner KB; DelGaudio NL; Durani V; Kini M; Rex M; Tian HS; Zuber J; Baslan T; Lowe SW; Rienhoff HY; Letai A; Levine RL; Armstrong SA
Cancer Discov; 2020 Oct; 10(10):1500-1513. PubMed ID: 32606137
[TBL] [Abstract][Full Text] [Related]
23. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
[TBL] [Abstract][Full Text] [Related]
24. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.
Sun Y; Zhou B; Mao F; Xu J; Miao H; Zou Z; Phuc Khoa LT; Jang Y; Cai S; Witkin M; Koche R; Ge K; Dressler GR; Levine RL; Armstrong SA; Dou Y; Hess JL
Cancer Cell; 2018 Oct; 34(4):643-658.e5. PubMed ID: 30270123
[TBL] [Abstract][Full Text] [Related]
25. HOXA9 transcription factor is a double-edged sword: from development to cancer progression.
Shenoy US; Adiga D; Alhedyan F; Kabekkodu SP; Radhakrishnan R
Cancer Metastasis Rev; 2024 Jun; 43(2):709-728. PubMed ID: 38062297
[TBL] [Abstract][Full Text] [Related]
26. CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in
Schneider P; Wander P; Arentsen-Peters STCJM; Vrenken KS; Rockx-Brouwer D; Adriaanse FRS; Hoeve V; Paassen I; Drost J; Pieters R; Stam RW
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686014
[TBL] [Abstract][Full Text] [Related]
27. Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies.
Gaál Z
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671446
[TBL] [Abstract][Full Text] [Related]
28. Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells.
Bulut I; Lee A; Cevatemre B; Ruzic D; Belle R; Kawamura A; Gul S; Nikolic K; Ganesan A; Acilan C
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497494
[TBL] [Abstract][Full Text] [Related]
29. Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential.
Tang L; Peng L; Tan C; Liu H; Chen P; Wang H
Cancer Cell Int; 2022 Nov; 22(1):349. PubMed ID: 36376832
[TBL] [Abstract][Full Text] [Related]
30. Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.
Alexandrova E; Salvati A; Pecoraro G; Lamberti J; Melone V; Sellitto A; Rizzo F; Giurato G; Tarallo R; Nassa G; Weisz A
Front Genet; 2022; 13():864612. PubMed ID: 35495127
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.
Salmon JM; Todorovski I; Stanley KL; Bruedigam C; Kearney CJ; Martelotto LG; Rossello F; Semple T; Arnau GM; Zethoven M; Bots M; Bjelosevic S; Cluse LA; Fraser PJ; Litalien V; Vidacs E; McArthur K; Matthews AY; Gressier E; de Weerd NA; Lichte J; Kelly MJ; Hogg SJ; Hertzog PJ; Kats LM; Vervoort SJ; De Carvalho DD; Scheu S; Bedoui S; Kile BT; Lane SW; Perkins AC; Wei AH; Dominguez PM; Johnstone RW
Cancer Discov; 2022 Jun; 12(6):1560-1579. PubMed ID: 35311997
[TBL] [Abstract][Full Text] [Related]
32. Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins.
Zhang J; Gao X; Yu L
Front Oncol; 2021; 11():741746. PubMed ID: 34540702
[TBL] [Abstract][Full Text] [Related]
33. Gene Transcription as a Therapeutic Target in Leukemia.
Khamidullina AI; Varlamova EA; Hammoud NA; Yastrebova MA; Bruter AV
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298959
[TBL] [Abstract][Full Text] [Related]
34. HDAC Inhibitors in Acute Myeloid Leukemia.
San José-Enériz E; Gimenez-Camino N; Agirre X; Prosper F
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31739588
[TBL] [Abstract][Full Text] [Related]
35. Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia.
Lambert M; Alioui M; Jambon S; Depauw S; Van Seuningen I; David-Cordonnier MH
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31213012
[TBL] [Abstract][Full Text] [Related]
36. Targeting epigenetics for cancer therapy.
Park JW; Han JW
Arch Pharm Res; 2019 Feb; 42(2):159-170. PubMed ID: 30806885
[TBL] [Abstract][Full Text] [Related]
37. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
39. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
40. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
